Spotlight
Video

ABSTRACT #336: FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.

imedex has 1159 videos Subscribe Here

Loading........
Description: Dr. Axel Grothey discusses Abstract #336: FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer at the ASCO GI meeting 2013
Shared By : imedex
Posted on : 02/04/13
Added : 5 years ago
Category : Colorectal Cancer